PE20191789A1 - Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa - Google Patents

Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa

Info

Publication number
PE20191789A1
PE20191789A1 PE2019002276A PE2019002276A PE20191789A1 PE 20191789 A1 PE20191789 A1 PE 20191789A1 PE 2019002276 A PE2019002276 A PE 2019002276A PE 2019002276 A PE2019002276 A PE 2019002276A PE 20191789 A1 PE20191789 A1 PE 20191789A1
Authority
PE
Peru
Prior art keywords
nadph oxidase
heterocyclic compounds
bicycle
inhibitors
compounds replaced
Prior art date
Application number
PE2019002276A
Other languages
English (en)
Inventor
Sukeerthi Kumar
Abraham Thomas
Sachin Sundarlal Chaudhari
Laxmikant Atmaram Gharat
Neelima Khairatkar-Joshi
Daisy Manish Shah
Indranil Mukhopadhyay
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PE20191789A1 publication Critical patent/PE20191789A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Referido a un compuesto, caracterizado porque se selecciona de: 6-(2-Clorofenil)-5-hidroxi-1,3-dimetil-1,7-dihidro-4H-pirazolo[3,4-b]piridin-4-ona; 6-(2-Clorofenil)-5-hidroxi-3-metil- 1-(2-morfolinoetil)-1H-pirazolo[3,4-b]piridin-4(7H)-ona, entre otros y su sal farmaceuticamente aceptable de los mismos. Estos compuestos heterociclicos biciclicos sustituidos inhiben la nicotinamida adenina dinucleotido fosfato oxidasa (NADPH oxidasa) y son utiles en el tratamiento o prevencion de diversas enfermedades, afecciones y/o trastornos mediados por la NADPH oxidasa. Tambien se refiere a procesos para su preparacion, compuestos intermediarios y composiciones farmaceuticas que los comprende.
PE2019002276A 2017-05-04 2018-05-04 Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa PE20191789A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721015787 2017-05-04
PCT/IB2018/053121 WO2018203298A1 (en) 2017-05-04 2018-05-04 Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors

Publications (1)

Publication Number Publication Date
PE20191789A1 true PE20191789A1 (es) 2019-12-24

Family

ID=62245373

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019002276A PE20191789A1 (es) 2017-05-04 2018-05-04 Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa

Country Status (16)

Country Link
US (1) US20200247800A1 (es)
EP (1) EP3619209A1 (es)
JP (1) JP2020518624A (es)
KR (1) KR20200013665A (es)
CN (1) CN110914263A (es)
AU (1) AU2018262528A1 (es)
BR (1) BR112019023109A2 (es)
CA (1) CA3062185A1 (es)
CL (1) CL2019003107A1 (es)
CO (1) CO2019013655A2 (es)
EA (1) EA201992343A1 (es)
MX (1) MX2019013148A (es)
PE (1) PE20191789A1 (es)
PH (1) PH12019502462A1 (es)
SG (1) SG11201910172VA (es)
WO (1) WO2018203298A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3114722A1 (en) * 2018-10-01 2020-04-09 Genzyme Corporation Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use
CN115215767B (zh) * 2021-04-16 2023-09-12 帕潘纳(北京)科技有限公司 制备2-氰基-3-乙氧基丙烯酸乙酯衍生物的方法
CN113292496B (zh) * 2021-05-17 2023-03-10 安徽联创生物医药股份有限公司 一种劳拉替尼中间体的合成方法
WO2023217764A1 (en) 2022-05-09 2023-11-16 Calliditas Therapeutics Suisse Sa Nox inhibitors for use in the treatment of alport syndrome

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070082910A1 (en) * 2003-04-08 2007-04-12 Mitsubishi Pharma Corporation Specific nad(p)h oxidase inhibitor
JP2007133750A (ja) * 2005-11-11 2007-05-31 Canon Inc 情報処理方法及び情報処理装置
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
FR2929276B1 (fr) * 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
GB201104600D0 (en) * 2011-03-18 2011-05-04 Pronoxis Ab New compounds and medical uses
EA037370B1 (ru) * 2015-11-25 2021-03-19 Эффектор Терапьютикс, Инк. eIF4A-ИНГИБИРУЮЩИЕ СОЕДИНЕНИЯ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ

Also Published As

Publication number Publication date
CN110914263A (zh) 2020-03-24
EA201992343A1 (ru) 2020-04-16
PH12019502462A1 (en) 2020-06-29
CO2019013655A2 (es) 2020-04-01
CL2019003107A1 (es) 2020-03-13
BR112019023109A2 (pt) 2020-05-26
US20200247800A1 (en) 2020-08-06
WO2018203298A1 (en) 2018-11-08
CA3062185A1 (en) 2018-11-08
JP2020518624A (ja) 2020-06-25
KR20200013665A (ko) 2020-02-07
SG11201910172VA (en) 2019-11-28
AU2018262528A1 (en) 2019-11-21
EP3619209A1 (en) 2020-03-11
MX2019013148A (es) 2019-12-18

Similar Documents

Publication Publication Date Title
PE20191789A1 (es) Compuestos heterociclicos biciclicos sustituidos como inhibidores de la nadph oxidasa
PE20211001A1 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b
MX2021011438A (es) Imidazopirrolopiridina como inhibidores de la familia de quinasas jak.
PE20050306A1 (es) Compuestos imidazol condensado, 2-piridilo sustituido como inhibidores del factor de crecimiento transformante (tgf)
CR10358A (es) Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos
PE20170693A1 (es) Derivados de imidazol pentaciclicos fusionados
PE20151332A1 (es) Compuestos de azabencimidazol
MX2019007073A (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak.
IL276501A (en) CGAS inhibitors containing 2,3,4,5-tetrahydro-1H-pyrado[B-4,3]indoles for the treatment of autoinflammatory diseases
PE20170128A1 (es) Compuestos para tratar atrofia muscular espinal
MX2021008145A (es) Polimorfo de macrociclo de diarilo.
SG11201907095UA (en) DERIVATIVES OF N-CYCLOALKYL/HETEROCYCLOALKYL-4-(IMIDAZO [1,2-a]PYRIDINE)PYRIMIDIN-2-AMINE AS THERAPEUTIC AGENTS
PE20160588A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
CO6531468A2 (es) Derivados de imidazo[1,2-b] piridazina y su uso como inhibidores de pde 10
NZ631187A (en) Tricyclic quinoline and quinoxaline derivatives
CL2011002837A1 (es) Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros.
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
MX2017013219A (es) Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos.
PE20181008A1 (es) Compuesto piranodipiridinico
UY29239A1 (es) Nuevos derivados de piridotienopirimidina
CO6612202A2 (es) Inhibidores heterparílicos bicíclicos de pde4
WO2013042035A4 (en) Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
AR115782A1 (es) DERIVADOS DE ESPIROCROMANO, UN MÉTODO PARA SU PREPARACIÓN, INTERMEDIARIOS PARA SU SÍNTESIS, COMPOSICIÓN Y COMBINACIÓN FARMACÉUTICA QUE LOS COMPRENDEN Y EL USO DE LOS MISMOS EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS AL RECEPTOR NICOTÍNICO DE ACETILCOLINA a7
UY32280A (es) DERIVADOS DE 6-CICLOAMINO-3-(1H-PIRROLO[2,3-b]PIRIDIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACIÓN Y SU APLICACIÓN EN TERAPÉUTICA
MX2021000683A (es) Derivados de imidazo[1,2-b]piridazina como inhibidores de trk.